A treatment recommendation is only as good as the pathway after it

A patient sits across from you. You tell them a biologic or specialist therapy could help but then you tell them it isn’t available through the NHS. NICE approval is built on population-level evidence and cost thresholds, not the person in front of you. There will always be patients who don’t meet the criteria, even when you’re confident the treatment is right for them.

Self-funding is often the only route left. And for many private practices, that’s where things get harder, not easier.

You can write the prescription. What you usually can’t do – without hiring people or building systems that have nothing to do with clinical are – is manage everything that comes after: sourcing the medicine, coordinating payment, arranging delivery, training the patient to administer it safely and keeping track of them over months of ongoing treatment. Larger hospital groups with an in-house pharmacy can absorb that. A dermatology, respiratory or neurology consultant running an independent practice usually can’t.

The result is a gap between recommending treatment and a patient actually starting it. Some patients stall. Some go looking for another way. Either way, the practice loses the follow-through on a recommendation it made in good faith, and the patient loses time they don’t have.

What we’re building

Sciensus already runs complex clinical homecare pathways for over 600 consultants and clinics across the UK, supporting more than 300,000 patients a year with complex medicines delivered outside hospital walls. Most of that work has been through the NHS and pharmaceutical industry partners.

This year we started a pilot extending the same model to self-funded private care. The idea is simple: once you identify a patient who’s paying for their own treatment, we take on everything from that point except the clinical decision itself. Onboarding, payment coordination, medicine delivery, prescription reminders and clinical support at home through our network of specialist nurses where the treatment needs it. You stay in charge of the treatment plan and get relevant updates back, without taking on the operational load of running a pharmacy.

Why this works

We have over 30 years’ experience running exactly this model for NHS and industry-funded patients at scale, and a specific reason for extending it to self-pay: consultants running smaller, independent practices kept telling us the same thing. They can identify eligible patients. They just don’t have the infrastructure to support them once the prescription is written and building it themselves isn’t viable.

If that sounds familiar, we’d love to have a conversation. Especially if you’re at a practice without an attached pharmacy, or you’re seeing self-funded patients whose access has been slower or more complicated than it should be.